Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Declines By 26.4%

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) saw a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 42,300 shares, a decrease of 26.4% from the March 31st total of 57,500 shares. Based on an average daily volume of 670,400 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.4% of the company’s stock are short sold.

Institutional Trading of MIRA Pharmaceuticals

An institutional investor recently bought a new position in MIRA Pharmaceuticals stock. Praetorian Wealth Management Inc. acquired a new stake in shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 27,500 shares of the company’s stock, valued at approximately $30,000. Praetorian Wealth Management Inc. owned about 0.19% of MIRA Pharmaceuticals at the end of the most recent reporting period. 35.16% of the stock is currently owned by institutional investors and hedge funds.

MIRA Pharmaceuticals Stock Performance

NASDAQ:MIRA opened at $0.86 on Friday. MIRA Pharmaceuticals has a fifty-two week low of $0.76 and a fifty-two week high of $7.98. The firm has a 50-day simple moving average of $1.06 and a two-hundred day simple moving average of $1.59.

MIRA Pharmaceuticals (NASDAQ:MIRA) last posted its quarterly earnings results on Monday, April 1st. The company reported ($0.19) EPS for the quarter. On average, research analysts forecast that MIRA Pharmaceuticals will post -0.39 earnings per share for the current fiscal year.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.